Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Cella, David; Evans, JS; Feuilly, Marion; Neggers, Sebastian J C M M; Genechten, Dirk Van; Herman, Jackie; Khan, Mohid S.

doi:10.1007/s12325-020-01600-x

Cited by 15 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As evidenced by the COVID-19 pandemic, stringent public health measures have disrupted routine clinical care for patients [58]. Home treatment options, therefore, allow for effective patient management in times of limited availability of HCPs and healthcare-setting resources [24,25]. Treatments for home injection are increasingly being developed for a wide range of chronic illnesses, including plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis, and their adoption is expected to rise.…”

Section: Discussionmentioning

confidence: 99%

“…Shared treatment decision-making accommodating patients' individual preferences has been associated with increased adherence and improved clinical outcomes [26]. However, despite the development of home injection treatment options for SSA injections, the advantages and disadvantages of home injections have not been widely examined [24]. A systematic literature review was therefore conducted with the primary objective of identifying and summarizing outcomes related to home administration of SSAs by self/partner injections (LAN) or injections by a HCP (OCT and LAN).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating Home Injection Compared with Healthcare-Setting Injection of Somatostatin Analogs: A Systematic Literature Review

Boguszewski

Artignan

Korbonits

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogues (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods MEDLINE/Embase/the Cochrane Library (2001–September 2021), key congresses (2019–2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results Overall, 12 studies were included, all reporting on SSAs (lanreotide autogel/depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (> 75% patients) was reported for home injections. Self- or partner-injection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluating Home Injection Compared with Healthcare-Setting Injection of Somatostatin Analogs: A Systematic Literature Review

Boguszewski

Artignan

Korbonits

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“… 15 Agonistic analogs, such as octreotide and lanreotide, have been approved for gastrointestinal NETs or P‐NETs in many countries. 16 …”

Section: Neuroendocrine Tumormentioning

confidence: 99%

“…The halflife of somatostatin in the body is very short (approximately 1-3 minutes), and many SSAs have been developed to maintain sufficient serum concentrations 15. Agonistic analogs, such as octreotide and lanreotide, have been approved for gastrointestinal NETs or P-NETs in many countries 16. 3 | S O M ATOS TATI N R ECE P TO R SCINTI G R APHYThe diagnosis of GEP-NETs has been difficult over an extended period.…”

mentioning

confidence: 99%

Neuroendocrine tumor theranostics

Ichikawa

Kobayashi²,

Takano

et al. 2022

Cancer Science

View full text Add to dashboard Cite

Theranostics is a term coined by combining the words "therapeutics" and "diagnostics," referring to single chemical entities developed to deliver therapy and diagnosis simultaneously. Neuroendocrine tumors are rare cancers that occur in various organs of the body, and they express neuroendocrine factors such as chromogranin A and somatostatin receptor. Somatostatin analogs bind to somatostatin receptor, and when combined with diagnostic radionuclides, such as gamma-emitters, are utilized for diagnosis of neuroendocrine tumor. Somatostatin receptor scintigraphy when combined with therapeutic radionuclides, such as beta-emitters, are effective in treating neuroendocrine tumor as peptide receptor radionuclide therapy. Somatostatin receptor scintigraphy and peptide receptor radionuclide therapy are some of the most frequently used and successful theranostics for neuroendocrine tumor. In Japan, radiopharmaceuticals are regulated under a complex law system, creating a significant drug lag, which is a major public concern. It took nearly 10 years to obtain the approval for somatostatin receptor scintigraphy and peptide receptor radionuclide therapy use by the Japanese government. In 2021, 111 Lu-DOTATATE (Lutathera), a drug for peptide receptor radionuclide therapy, was covered by insurance in Japan. In this review, we summarize the history of the development of neuroendocrine tumor theranostics and theranostics in general, as therapeutic treatment for cancer in the future. Furthermore, we briefly address the Japanese point of view regarding the development of new radiopharmaceuticals.

show abstract

“…LAN and OCT are not, however, approved for self-or partner-injection in the US [12,15]. Home injection options allow for more autonomy in patients' care, in particular for those with limited time or mobility, as observed in acromegaly patients with more severe joint disease [21][22][23], and have been increasingly used in times of high burden on the healthcare system, such as during the COVID-19 pandemic [24,25].…”

Section: Introductionmentioning

confidence: 99%

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

et al. 2022

View full text Add to dashboard Cite

Purpose A systematic literature review was conducted to assess the use of home injections (self/partner/healthcare provider [HCP]-administered) of somatostatin analogs (SSAs) as an alternative to healthcare-setting injections in patients with acromegaly and neuroendocrine tumors (NETs). Methods MEDLINE/Embase/the Cochrane Library (2001( -September 2021, key congresses (2019-2021), and bibliographies of relevant systematic reviews were searched. Eligible studies reported on efficacy/effectiveness, safety, adherence, patient-reported outcomes (PROs), and economic outcomes in populations receiving home injections of SSAs. Results Overall, 12 studies were included, all reporting on SSAs (lanreotide Autogel/Depot or octreotide long-acting release) in acromegaly or NETs. Across four studies, home injection was associated with similar disease control in patients with acromegaly/ NETs compared with healthcare-setting administration. High rates of treatment adherence were shown in two studies of patients with acromegaly receiving lanreotide injections at home. Two studies reported non-serious adverse events; incidence of adverse reactions was similar in both the home and healthcare administration settings. Preference for injection setting varied between studies and indications; nonetheless, higher satisfaction/convenience (>75% patients) was reported for home injections. Self-or partnerinjection was associated with economic savings compared with administration in the healthcare setting across five studies. Conclusion Efficacy/effectiveness, adherence, and safety outcomes of SSAs in the home injection setting were similar to those in the healthcare setting, with high reported satisfaction and convenience. Self/partner injection also resulted in cost savings. These findings provide a basis to understand outcomes related to home injection and encourage healthcare providers to discuss optimal treatment choices with their patients. Plain language summaryAcromegaly and neuroendocrine tumors (NETs) are two diseases that affect the production of hormones, leading to a variety of symptoms in different parts of the body. Patients can be treated with medications called somatostatin analogs, which include lanreotide Autogel/Depot (LAN) and octreotide long-acting release (OCT). These treatments are given by injections, usually performed by a doctor or nurse in a healthcare setting such as a hospital or clinic. However, patients can sometimes receive LAN or OCT injections at home by a healthcare professional or-for LAN onlyindependently by a partner or the patient themself. Home injection may be less disruptive for patients and could free up healthcare resources, but there is limited evidence to support the choice. To address this, we reviewed all publications on home injection of somatostatin analogs in the last 20 years, finding 12 relevant studies. Results generally showed that

show abstract

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Cited by 15 publications

References 41 publications

Evaluating Home Injection Compared with Healthcare-Setting Injection of Somatostatin Analogs: A Systematic Literature Review

Evaluating Home Injection Compared with Healthcare-Setting Injection of Somatostatin Analogs: A Systematic Literature Review

Neuroendocrine tumor theranostics

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review

Contact Info

Product

Resources

About